Results 261 to 270 of about 2,450,308 (424)

Risk Evaluation of Point-of-Care Testing (POCT) Devices: Insights From a Tertiary Care Hospital. [PDF]

Cureus
Satheesh SS, Mourya Gv PS.
europepmc   +1 more source

The Future of Point–of–Care Testing Using C-Reactive Protein – An Ideal Tool for Diagnosis, Prognosis and Therapy Management [PDF]

, 2006
Eldri Prestegård
openalex   +1 more source

Exploration of heterogeneity and recurrence signatures in hepatocellular carcinoma

Molecular Oncology, EarlyView.
This study leveraged public datasets and integrative bioinformatic analysis to dissect malignant cell heterogeneity between relapsed and primary HCC, focusing on intercellular communication, differentiation status, metabolic activity, and transcriptomic profiles.
Wen‐Jing Wu, Jianchao Wang, Fuqing Chen, Xuefeng Wang, Bin Lan, Ruyi Fu, Hong Wen, Fangfang Chen, Wei Hong, Tian‐Yu Tang, Ying He, Gang Chen, Jianyin Zhou, Hai‐Long Piao, Di Chen, Shu‐Yong Lin   +15 more
wiley   +1 more source

Advancements in nanobiosensor technologies for in-vitro diagnostics to point of care testing. [PDF]

Heliyon
Kim C, Kang MS, Raja IS, Joung YK, Han DW.   +4 more
europepmc   +1 more source

Point-of-care Test Identifies Diabetic Ketoacidosis at Triage [PDF]

, 2006
Rosanne Naunheim, Timothy J. Jang, Gerald A. Banet, Alec Richmond, Janet B. McGill   +4 more
openalex   +1 more source

A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival

Molecular Oncology, EarlyView.
There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...
Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas   +20 more
wiley   +1 more source

Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections. [PDF]

Diagnostics (Basel)
Lakshmanan K, Liu BM.
europepmc   +1 more source

CE-Kennzeichnung von Point-of-Care-Testsystemen / CE marking of point-of-care test devices [PDF]

, 2006
Micha Nübling
openalex   +1 more source

Germline variants in CDKN2A wild‐type melanoma prone families

Molecular Oncology, Volume 19, Issue 5, Page 1493-1507, May 2025.
Among melanoma‐prone families, wild‐type for CDKN2A and CDK4, some have pathogenic variants in genes not usually linked to melanoma. Furthermore, rare XP‐related variants and variants in MC1R are enriched in such families. Germline pathogenic variants in CDKN2A are well established as an underlying cause of familial malignant melanoma. While pathogenic
Gjertrud T. Iversen, Marie Loeng, Amalie Lund Holth, Per E. Lønning, Jürgen Geisler, Stian Knappskog   +5 more
wiley   +1 more source

Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy. [PDF]

J Comp Eff Res
Garcia D, Ruffolo A, Mooradally AW, Zhou A, Lazaridis E, Laurelli B.   +5 more
europepmc   +1 more source